Cancer drugs' sexual toxicity warrants a "call to action" among oncologists to address the problem. (Lancet Oncology) U.S.

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as first-line treatment for adults with unresectable or metastatic HCC.

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

The FDA has granted approval to nivolumab plus ipilimumab for use in unresectable or metastatic hepatocellular carcinoma.

CTLA4 Inhibitors Market forecast to 2035 covers market size, key trends, competitive landscape, and growth opportunities in cancer immunotherapy and autoimmune diseases.

Bristol Myers Squibb BMY announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus ...